Skip to main content

Advertisement

SpringerLink
Log in

Can objective parameters in optical coherence tomography be useful markers in the treatment and follow-up of type 1 and type 2 macular neovascularizations related to neovascular age-related macular degeneration?

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to compare the responses of type 1 and type 2 macular neovascularizations (MNV) caused by neovascular type age-related macular degeneration (n-AMD) to intravitreal anti-vascular endothelial growth factor (VEGF) treatments using quantitative parameters determined by optical coherence tomography (OCT). Additionally, it was also intended to assess the connections between these quantitative parameters and changes in best-corrected visual acuity (BCVA) and the number of intravitreal anti-VEGF injections required within a year.

Materials and methods

In our retrospective and observational study, the data of 90 eyes of 90 patients diagnosed with n-AMD and treated with intravitreal anti-VEGF with the "Pro re nata" method were evaluated. Subtypes of existing MNVs were distinguished with previously taken optical coherence tomography angiography (OCTA) images. In spectral domain OCT examinations, central macular thickness (CMT) and central macular volume (CMV) values were recorded at baseline and 12th month. The number of intravitreal anti-VEGF injections during the 12 month follow-up period was also recorded for each patient. Obtained data were compared between MNV types.

Results

Of the n-AMD cases examined in the study, 56.66% had type 1 MNV and 43.34% had type 2 MNV. The mean baseline BCVA logMAR values in eyes with type 2 MNV (1.15 ± 0.43) were higher than those observed in eyes with type 1 MNV (0.76 ± 0.42) (p = 0.001). Similarly, mean baseline CMT and CMV values in eyes with type 2 MNV were higher than those observed in eyes with type 1 MNV (respectively 424.89 ± 49.46 μm vs. 341.39 ± 37.06 μm; 9.17 ± 0.89 μm3 vs. 8.49 ± 0.53 μm3; p < 0.05). After 12 months of treatment, logMAR values of BCVA (0.86 ± 0.42) in subjects with type 2 MNV were higher than those in subjects with type 1 MNV (0.57 ± 0.37) (p = 0.001). Mean CMT and CMV values at 12th month in subjects with type 2 MNV (379.11 ± 46.36 μm and 8.66 ± 0.79 μm3, respectively) were observed to be higher than those with type 1 MNV (296.95 ± 33.96 μm and 8.01 ± 0.52 mm3, respectively) (p < 0.05). In type 2 MNVs, positive correlations were observed between both baseline and 12th month BCVA logMAR values and baseline CMV (p < 0.05). Similarly, in type 2 MNVs, a positive correlation was observed between 12th month BCVA logMAR values and 12th month CMV (p < 0.05). The total number of intravitreal anti-VEGF injections at 12 months was similar in both groups (p = 0.851).

Conclusion

In this study, in which we performed a subtype analysis of MNV cases, we observed that the visual function was worse at the beginning and the end of the 12th month, and the CMT and CMV values were higher in the type 2 MNV group compared to the type 1 MNV cases. In addition, we found significant correlations between BCVA logMAR values and CMV values in type 2 MNV cases. In the follow-up of these cases, CMT, which is a more widely used quantitative method, and CMV, which is a newer OCT measurement parameter, may be more useful in patient follow-up and evaluation of treatment efficacy, especially for type 2 MNV cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Singer, MJFR, (2014) Advances in the management of macular degeneration. 6

  2. Keane PA et al (2012) Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol 57(5):389–414

    Article  PubMed  Google Scholar 

  3. Schmidt-Erfurth U et al (2014) Guidelines for the management of neovascular age-related macular degeneration by the European society of retina specialists (EURETINA). Br J Ophthalmol 98(9):1144–1167

    Article  PubMed  Google Scholar 

  4. Schmidt-Erfurth U, Waldstein SM (2016) A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 50:1–24

    Article  CAS  PubMed  Google Scholar 

  5. Ying GS et al (2013) Baseline predictors for 1-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 120(1):122–129

    Article  PubMed  Google Scholar 

  6. Hörster R et al (2011) Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 249(5):645–652

    Article  PubMed  Google Scholar 

  7. Chae B et al (2015) Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy. Invest Ophthalmol Vis Sci 56(9):5040–5047

    Article  CAS  PubMed  Google Scholar 

  8. Freund KB et al (2015) Treat-and-extend regimens with anti-vegf agents in retinal diseases: a literature review and consensus recommendations. Retina 35(8):1489–1506

    Article  CAS  PubMed  Google Scholar 

  9. Nemcansky J et al (2019) Response to aflibercept therapy in three types of choroidal neovascular membrane in neovascular age-related macular degeneration: real-life evidence in the Czech republic. J Ophthalmol 2019:2635689

    Article  PubMed  PubMed Central  Google Scholar 

  10. Spaide RF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26(4):383–390

    Article  PubMed  Google Scholar 

  11. Yaylali SA et al (2012) The relationship between optical coherence tomography patterns, angiographic parameters and visual acuity in age-related macular degeneration. Int Ophthalmol 32(1):25–30

    Article  PubMed  Google Scholar 

  12. Ting TD et al (2002) Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol 120(6):731–737

    Article  PubMed  Google Scholar 

  13. Ou WC et al (2017) Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases. Am J Ophthalmol 180:8–17

    Article  CAS  PubMed  Google Scholar 

  14. Gerding H et al (2011) Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol 249(5):653–662

    Article  CAS  PubMed  Google Scholar 

  15. Zweifel SA et al (2009) Outer retinal tubulation: a novel optical coherence tomography finding. Arch Ophthalmol 127(12):1596–1602

    Article  PubMed  Google Scholar 

  16. von der Burchard C et al (2018) Retinal volume change is a reliable OCT biomarker for disease activity in neovascular AMD. Graefes Arch Clin Exp Ophthalmol 256(9):1623–1629

    Article  PubMed  Google Scholar 

  17. Gianniou C et al (2015) Refractory intraretinal or subretinal fluid in neovascular age-related macular degeneration treated with intravitreal Ranizubimab: functional and structural outcome. Retina 35(6):1195–1201

    Article  CAS  PubMed  Google Scholar 

  18. Espina M et al (2016) Outer retinal tubulations response to anti-VEGF treatment. Br J Ophthalmol 100(6):819–823

    Article  PubMed  Google Scholar 

  19. Fung AE et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143(4):566–583

    Article  MathSciNet  CAS  PubMed  Google Scholar 

  20. Lee JY, Chung H, Kim HC (2016) Changes in fundus autofluorescence after anti-vascular endothelial growth factor according to the type of choroidal neovascularization in age-related macular degeneration. Korean J Ophthalmol 30(1):17–24

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Liakopoulos S et al (2008) Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 49(11):5048–5054

    Article  PubMed  Google Scholar 

  22. Sayed KM et al (2011) Early visual impacts of optical coherence tomographic parameters in patients with age-related macular degeneration following the first versus repeated ranibizumab injection. Graefes Arch Clin Exp Ophthalmol 249(10):1449–1458

    Article  CAS  PubMed  Google Scholar 

  23. Ristau T et al (2013) Prognostic factors for long term visual acuity outcome after ranibizumab therapy in patients with neovascular age-related macular degeneration. J Clin Exp Ophthalmol 4(1):1–6

    Article  Google Scholar 

Download references

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

  1. Polatlı Duatepe State Hospital, Ankara, Turkey

    Osman Özen

  2. Etlik City Hospital, University of Health Sciences, Ankara, Turkey

    Ayşe Gül Koçak Altıntaş

Authors
  1. Osman Özen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayşe Gül Koçak Altıntaş
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Involved in design and conduct of this study (OÖ, AKA); involved in collection, management, analysis, and interpretation of the data (OÖ, AKA); involved in preparation, review, or approval of the manuscript (OÖ, AKA).

Corresponding author

Correspondence to Osman Özen.

Ethics declarations

Conflict of interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Özen, O., Koçak Altıntaş, A.G. Can objective parameters in optical coherence tomography be useful markers in the treatment and follow-up of type 1 and type 2 macular neovascularizations related to neovascular age-related macular degeneration?. Int Ophthalmol 44, 134 (2024). https://doi.org/10.1007/s10792-024-03073-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10792-024-03073-1

Keywords

Search

Navigation